Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation

References

• BERTZ, R. J. and GRANNEMAN, G. R., 1997, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32, 210–258.
   PubMed Web of Science ®Google Scholar
• BLOOMER, J. C., CLARKS, S. E. and CHENERY, R. J., 1995, Determination of P4501A2 activity in human liver microsomes using [3-14C-methyl]caffein. Xenobiotica, 25, 917–927.
   PubMed Web of Science ®Google Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–332.
   PubMed Web of Science ®Google Scholar
• CRESPI, C. L. and PENMAN, B. W., 1997, Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug—drug interactions. Advances in Pharmacology, 43, 171–188.
   PubMedGoogle Scholar
• DRAPER, A. J., MADAN, A. and PARKINSON A., 1997, Inhibition of Coumarin 7-hydroxylase activity in human liver microsomes. Archives of Biochemistry and Biophysics, 341, 47–61.
   Google Scholar
• EAGLING, V. A., TRA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107–114.
   PubMed Web of Science ®Google Scholar
• GHOSAL, A., SATOH, H., THOMAS, P. E., Busil, E. and MOORE, D., 1996, Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human and CDNA-expressed human cytochrome P450. Drug Metabolism and Disposition, 24, 940–947.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1997, Role of cytochrome P450 enzymes in drug—drug interactions. Advances in Pharmacology, 43, 7–35.
   PubMedGoogle Scholar
• HICKMAN, D., WANG, J. P., WANG, Y. and UNADKAT, J. D., 1998, Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metabolism and Disposition, 26, 207–215.
   PubMed Web of Science ®Google Scholar
• Hopkins, A., Price-Jones, M. J., Hughes, K. T., Eddershaw, P. J., Hood, S. R., Woodrooffe, A. J. and TARBrf, M. H., 1998, A high throughput screening assay for the inhibition of binding to CYP3A4 using SpA. 12th International conference on microsomes and drug oxidation, Montpellier, France.
   Google Scholar
• KIVISTO, K. T. and KROEMER, H. K., 1997, Use of probe drugs as predictors of drug metabolism in humans. Journal of Clinical Pharmacology, 37(1 Suppl), 40 S–48 S.
   Google Scholar
• KUPFERSCHMIDT, H. H., FATTINGER, K. E., HA, H. R., FOLIATH, F. and KRAHENBUHL, S., 1998, Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man British Journal of Clinical Pharmacology, 45, 355–359.
   Google Scholar
• LOWN, K. S., MAYO, R. R., LEICHTMAN, A. B., HSIAO, H. L., TURGEON, K., SCHMIEDLIN -REN, P., BROWN, M. B., Guo, W., Rossi, S. J., BENET, L. Z. and WATKINS, P. B., 1997, Pharmacokinetics and drug disposition: Role of intestinal P-glycoprotein (mdrl) in interpatient variation in the oral bioavailability of cyclosporine. Clinical Pharmacology & Therapeutics, 62, 248–260.
   Google Scholar
• LOWN, K. S., GHOSH, M. and WATKINS, P. B., 1998, Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical. Drug Metabolism Disposition, 26, 185–187.
   PubMed Web of Science ®Google Scholar
• LOWRY, O., ROSEBROUGH, A., FARR, A. and RANDALL, R., 1951, Protein measurement with the folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• MOODY, G. C., GRIFFIN, S. J., MATHER, A. N., McGiNixtri, D. F. and RILEY, R. J., 1999, Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica, 29, 53–75.
   PubMed Web of Science ®Google Scholar
• NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYERELSEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C. and NEBERT, D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1–42.
   PubMedGoogle Scholar
• NETTER, K. J., 1980, Inhibition of oxidative drug metabolism in microsomes. Pharmacology and Therapeutics, 10, 515–535.
   PubMed Web of Science ®Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, Y. H. A., 1995, CYTOCHROME P450 INITh3ITORS EVALUATION OF SPECIFICITIES IN THE in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Dispos, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• PATTEN, C. J., ISHIZAKI, H., AOYAMA, T., LEE, M., NING, S. M., HUANG, W., GONZALEZ, F. J. and YANG, C. S., 1992, Catalytic properties of the human cytochrome P450 2E1 produced by cDNA expression in mammalian cells. Archives of Biochemistry and Biophysics 229, 163–171.
   Web of Science ®Google Scholar
• PETER, R., BOCHER, R., BEAUNE, P. H., IwAsmu, M., GUENGERICH, P. and YANG, C. S., 1990, Hydroxylation of chlorzoxazone P-45011E1. Chemical Research in Toxicology, 3, 566–573.
   PubMed Web of Science ®Google Scholar
• RILEY, R. J. and HOWBROOK, D., 1997, In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [n-methyl-'4C] -erythromycin. Journal of Pharmacological and Toxi-cological Methods, 38, 189–193.
   PubMed Web of Science ®Google Scholar
• RING, B. J., BINKLEY, S. N., VANDENBRANDEN, M. and WRIGHTON, S..A., 1996, In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2 C19, CYP2D6 and CYP3A. British Journal of Clinical Pharmacology, 41, 181–186.
   PubMed Web of Science ®Google Scholar
• RODRIGUES, A. D., KUKULKA, M. J., SURBER, B. W., THOMAS, S. B., Ucmc, J. T., RoTERT, G. A., MICHEL, G., THOME -KROMER, B. and MACHINIST, J. M., 1994, Measurement of liver microsomal cytochrome P450 (CYP2 D6) activity using [0-methyl-14C] dextromethorphan. Analytical Biochemistry, 219, 309–320.
   Google Scholar
• SCHUETZ, E. G., BECK, W. T. and SCHUETZ, J. D., 1996, Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Molecular Pharmacology, 49, 311–318.
   PubMed Web of Science ®Google Scholar
• SHARER, J. E., SHIPLEY, L. A., VANDENBRANDEN, M. R., BRINKLEY, S. N. and WRIGHTON, S. A., 1995, Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey and cynomolgus monkey. Drug Metabolism and Disposition, 23, 1231–1241.
   PubMed Web of Science ®Google Scholar
• TESTA, B. and JENNER, P., 1981, Inhibitors of cytochrome P-450s and their mechanism of action. Drug Metabolism Reviews, 12, 1–117.
   PubMed Web of Science ®Google Scholar
• WARWICK, J. A. and CORRALL, R. J., 1998, Serious interaction between warfarin and oral terbinafine. British Medical Journal, 316, 440–447.
   PubMed Web of Science ®Google Scholar
• WYNALDA, M. A. and WIENKERs, L. C., 1997, Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metabolism and Disposition, 25, 1211–1214.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., INul, Y., YUN, C. H., MIMURA, M., GUENGERICH, F. P. and SHIMADA, T., 1992, Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialylamine s and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis, 13, 1789–1794.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., Guo, Z., PERSMARK, M., MIMURA, M., INOUE, K., GUENGERICH, F. P. and SHIMADA, 1994, Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Molecular Pharmacology, 46, 568–577.
   Google Scholar
• YIN, H., ANDERS, M. W., HIGGINS, L., KOWZEKWA, K. R. and JONES, J. P., 1995a, Designing safer chemicals: Predicting the rates of halogenated alkane metabolism. Proceedings of the National Academy of Sciences USA, 92,11076–11080.
   PubMed Web of Science ®Google Scholar
• YIN, H., JONES, J. P., and ANDERS, M. W., 1995b, Metabolism studies of 1,1,1 -trifluoro-2 -chloroethane, 1,2,-dichloro -1,1 -difluoroethane and 1-fluoro-1,1,2-trichloroethane. Chemical Research in Toxi-cology, 8, 262–268.
   PubMed Web of Science ®Google Scholar